Encouraging Uptake of Filgrastim BS and Lantus BS in 2015 in Japan is indicative of Japan being a key important market after the EU for growth of Biosimilar players in the next five years. Biosimilar of Complex mAb structure is an opportunity of cumulative market size of 300b in the next three years in Japan.